Skip to contentD
Dare Bioscience, Inc.
D
DAREDare Bioscience, Inc. Q3 2023 · 10-Q
Revenue$1.00M$1.00M— vs Q3 2022 Net Income-$8.30M-$8.30MN/M vs Q3 2022 EPS Diluted-$1.09-$1.09N/M vs Q3 2022 Operating Income-$8,396,415N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Dare Bioscience, Inc. · CIK 1401914 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$7,995,930N/M Margins · derivedOperating margin-839.6%
Net margin-829.9%
ended Sep 30, 2023 · filed Nov 9, 2023 · 40 d after period end